Eli Lilly | LLY - Ordinary Share Capital


Eli Lilly reported $943.5M in Ordinary Share Capital for its fiscal quarter ending in March of 2026.





Ordinary Share Capital Change Date
AbbVie USD 1.77B 1.75B Jun/2025
Abbott USD 1.74B 2.94M Mar/2026
ALKERMES USD 166.46M 855K Mar/2026
Amgen USD 540M 1000K Mar/2026
AstraZeneca USD 1.55B 73K Mar/2026
Baxter International USD 516.45M 2.17M Mar/2026
Biogen USD 146.7M 200K Sep/2025
Bristol-Myers Squibb USD 2.04B 1.74B Sep/2025
Coherus Biosciences USD 121.16M 4.92M Dec/2025
Drreddys Laboratories INR 832.69M 123K Mar/2026
Eli Lilly USD 943.5M 3.33M Mar/2026
Gilead Sciences USD 1.24B 1000K Mar/2026
GlaxoSmithKline GBP 4.05B 20.6M Mar/2026
Glaxosmithkline GBP 4.05B 20.6M Mar/2026
J&J USD 2.41B 1.35M Mar/2026
Medtronic USD 1.28B 1.38M Dec/2025
Merck USD 2.47B 12.72M Dec/2025
Neurocrine Biosciences USD 100.6M 500K Mar/2026
Novartis USD 1.91B 60K Mar/2026
Novartis USD 1.91B 60K Mar/2026
Novo Nordisk DKK 4.44B 0 Dec/2025
Perrigo USD 138.1M 500K Mar/2026
Pfizer USD 5.7B 13M Mar/2026
Phibro Animal Health USD 40.48M 0 Dec/2025
Prestige Brands USD 47.32M 765K Dec/2025
Regeneron Pharmaceuticals USD 105M 300K Mar/2026
Roche Holding CHF 795.62M 699.54K Dec/2025
Sanofi EUR 1.21B 8.25M Mar/2026
Sanofi EUR 1.2B 16.88M Mar/2026
United Therapeutics USD 42.16M 1.49M Mar/2026
Zoetis USD 420.35M 4.58M Mar/2026